ABBV vs INTU: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Intuit Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Intuit Inc. · Technology
$396.57
+37.7% upside to fair value
High Conviction
Grade A-
QuantHub Verdict
INTU has more upside to fair value
(+37.7%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
INTU |
| Current Price |
$208.05 |
$396.57 |
| Fair Value Estimate |
$217.50 |
$546.00 |
| Upside to Fair Value |
+4.5%
|
+37.7%
|
| Market Cap |
$367.9B |
$110.4B |
| Forward P/E |
14.9x
|
19.5x
|
| EV / EBITDA |
16.7x
|
19.0x
|
| Price / Sales |
6.1x
|
5.9x
|
| Price / FCF |
20.9x
|
18.1x
|
| Revenue Growth YoY |
+8.6%
|
+15.6%
|
| Gross Margin |
83.7%
|
80.8%
|
| Operating Margin |
34.7%
|
26.1%
|
| Return on Equity |
-129.24%
|
19.6%
|
| Dividend Yield |
3.2% |
1.17% |
| FCF Yield |
4.78%
|
5.51%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Intuit is a near-monopoly financial operating system for 60+ million American households and small businesses. TurboTax handles 40%+ of US e-filed returns; QuickBooks is so deeply embedded in SMB workflows it has become the default accounting standard. The stock has fallen 51% from its 2025 high as markets price in AI disruption that has not materialized at scale and may not, since tax complexity…
Accumulation Zones
| Metric |
ABBV |
INTU |
| Zone Low |
$163.13 |
$410.00 |
| Zone High |
$184.88 |
$464.00 |
| In Buy Zone? |
No
|
Yes
|